ViiV Starts Phase III With Two-Drug HIV Regimen In Naïve Patients
ViiV Healthcare begins a Phase III program for a two-drug regimen for adults with HIV who are treatment naïve, however, clinical data proving both long-term safety and efficacy will be crucial for commercial success.
You may also be interested in...
ViiV Healthcare is set to start Phase III studies of its next-generation integrase inhibitor cabotegravir as a long-acting injectable for the prevention of HIV. The head-to-head study will compare it with Gilead’s market leading oral PrEP therapy Truvada in pre-exposure prohylaxis in both men and women.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.